{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '11.', 'REFERENCES', 'Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The', 'European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life', 'instrument for use in international clinical trials in oncology. J Natl Cancer Institute.', '1993 Mar 3;85(5):365-76.', 'Afifi S, Michael A, Lesokhin A. Immunotherapy: A New Approach to Treating Multiple', 'Myeloma with Daratumumab and Elotuzumab. Ann Pharmacother. 2016;50(7):555-68', 'Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, et al. The', 'pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther.', '2009;330(3):932-8.', 'Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al.', \"Development of the National Cancer Institute's patient-reported outcomes version of the\", 'common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst.', '2014;106(9).', 'Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, et al. APRIL is', 'critical for plasmablast survival in the bone marrow and poorly expressed by early-life', 'bone marrow stromal cells. Blood. 2008;111(5):2755-64.', 'Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E, et al. An international field study', 'of the reliability and validity of a disease-specific questionnaire module (the QLQ-', 'MY20) in assessing the quality of life of patients with multiple myeloma. European', 'Journal of Cancer. 2007 Jul 31;43(11):1670-8.', 'Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, et al., editors.', 'B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells', '(CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I', 'Study. Abstract 1147. American Society of Hematology (ASH) 58th Annual Meeting &', 'Exposition December 3rd to 6th, 2016; 2016 05December 2016; San Diego, CA.', 'https://ash.confex.com/ash/2016/webprogram/Paper92775.html.', 'DARZALEX (daratumumab) injection, for intravenous use Full Prescription Information.', 'In: Janssen Biotech I, editor.', 'ittps://wwwdarzalexhcpcom/shared/product/darzalex/darzalex-prescribing-', 'informationpdf. Horsham, PA 19044 2017. p. 9.', 'de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al.', 'Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of', 'multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-8', 'Dougherty BE, Nichols JJ, Nichols KK. Rasch analysis of the Ocular Surface Disease', 'Index (OSDI). Invest Ophthalmol Vis Sci. 2011;52(12):8630-5.', 'GSK2857916 IB [GlaxoSmithKline Document Number 2013N175128_04 Report Date', '26-APRIL-2018', '100']['2017N330177_04', 'CONFIDENTIAL', '205678', 'H\u00e1jek R, Masszi T, Petrucci MT, Palumbo A, Rosi\u00f1ol L, Nagler A, et al. A randomized', 'phase III study of carfilzomib VS low-dose corticosteroids with optional', 'cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia.', '2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176.', 'Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of type I error', 'probability spending functions. Stat Med. 90;9(12):1439-45.', 'Janssen-Cilag International NV. Darzalex (daratumumab) summary of Product', 'Characteristics. In: Janssen-Cilag International NV, editor.', 'tp://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-', '-', 'Product_Information/human/004077/WC500207296pdf. B-2340 Beerse, Belgium 2016.', 'Jiang C, Loo WM, Greenley EJ, Tung KS, Erickson LD. B cell maturation antigen', 'deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J', 'Immunol. 2011;186(11):6136-47.', \"Kirwan C, Lanigan B, O'Keefe M. Vision-related quality of life assessment using the\", 'NEI-VFQ-25 in adolescents and young adults with a history of congenital cataract.', 'J', 'Pediatr Ophthalmol Strabismus. 2012;49(1):26-31.', 'Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy.', 'Annu Rev Immunol. 2013; 31:51-72.', 'Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P.', 'Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer.', '2012;12(12):860-75.', 'Kumar S, et al. International Myeloma Working Group consensus criteria for response', 'and minimal residual disease assessment in multiple myeloma. The Lancet Oncology.', '2016;17: e328-e346.', 'Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, et al. Response', 'rate, durability of response, and survival after thalidomide therapy for relapsed multiple', 'myeloma. Mayo Clin Proc. 2003;78(1):34-9.', 'Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of', 'progression and survival in multiple myeloma relapsing after therapy with IMiDs and', 'bortezomib: a multicenter international myeloma working group study. Leukemia.', '2012;26(1):149-57.', 'Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al.', 'Improved survival in multiple myeloma and the impact of novel therapies. Blood.', '2008;111(5):2516-20.', 'Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al.', 'Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc.', '2004;79(7):867-74.', '101']\n\n###\n\n", "completion": "END"}